Henry Schein, Inc. has seen significant growth in its stock and earnings, reporting impressive Q4 2025 results with adjusted earnings per share of $1.34 and net sales of $3.44 billion. This performance has led to upgrades from multiple analysts, who have set new price targets between $92 and $104. The surge follows a 24% increase in stock value over the previous months, driven by exclusive distribution rights for innovative healthcare technologies. Despite facing challenges with organic revenue and cash flow, the company is implementing a strategic roadmap to enhance profitability and focus on high-margin growth areas.
Loading timeline…
